Glenmark Pharmaceuticals rises 5% on launching first 3-drug FDC for type-2 diabetes in India
“This FDC has been launched under the brand name Zita®-PioMet,” the company said in a BSE filing. “This offers patients with Type 2 diabetes the convenience of once-daily dosing to improve their glycemic control and achieve the targeted HbA1c within 24 weeks,” it added.
